A Post-marketing Safety Study to Investigate the Risk of Serious CV Events among Galcanezumab (Emgality®) Users Using the Japan Medical Data Center Claim Database (I5Q-JE-B007) | HMA-EMA Catalogues of real-world data sources and studies